Profile data is unavailable for this security.
About the company
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of therapeutics for a range of cancer indications. The Company's product candidates are galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor. GPS is a cancer immunotherapeutic agent licensed by Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed by GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of mainland China, Hong Kong, Macau, and Taiwan.
- Revenue in USD (TTM)0.00
- Net income in USD-25.94m
- Incorporated2006
- Employees15.00
- LocationSellas Life Sciences Group Inc7 TIMES SQUARE, SUITE 2503NEW YORK 10036United StatesUSA
- Phone+1 (646) 200-5278
- Fax+1 (302) 636-5454
- Websitehttps://www.sellaslifesciences.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Agomab Therapeutics NV | 0.00 | -67.19m | 780.76m | 62.00 | -- | -- | -- | -- | -1.38 | -1.38 | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -23.60 | 0.009 | -- | -- | -- | -306.21 | -- | -- | -- |
| Compass Pathways PLC (ADR) | 0.00 | -237.32m | 783.16m | 166.00 | -- | 17.62 | -- | -- | -2.68 | -2.68 | 0.00 | 0.3916 | 0.00 | -- | -- | 0.00 | -94.37 | -45.17 | -169.95 | -49.01 | -- | -- | -- | -- | -- | -2.19 | 0.4541 | -- | -- | -- | -30.94 | -- | -- | -- |
| MapLight Therapeutics Inc | 0.00 | -92.43m | 783.59m | 109.00 | -- | -- | -- | -- | -2.23 | -2.23 | 0.00 | 1.54 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -39.26 | -- | -- | -- |
| BridgeBio Oncology Therapeutics Inc | 0.00 | 4.72m | 802.29m | -- | 50.25 | 1.25 | -- | -- | 0.1996 | 0.1996 | 0.00 | 8.05 | 0.00 | -- | -- | -- | 2.44 | -- | 2.45 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 18,328.62 | -- | -- | -- |
| Annexon Inc | 0.00 | -208.88m | 809.46m | 99.00 | -- | 3.99 | -- | -- | -1.39 | -1.39 | 0.00 | 1.40 | 0.00 | -- | -- | 0.00 | -68.11 | -42.65 | -76.07 | -45.54 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -2.95 | -- | -43.78 | -- |
| Evommune Inc | 3.00m | -66.26m | 819.63m | 45.00 | -- | -- | -- | 273.21 | -2.20 | -2.20 | 0.0997 | 2.85 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -2,158.80 | -- | -- | -- | 0.0086 | -- | 40.00 | -- | -100.59 | -- | -- | -- |
| Kalvista Pharmaceuticals Inc | 15.12m | -210.31m | 822.89m | 270.00 | -- | 48.40 | -- | 54.43 | -3.95 | -3.95 | 0.2838 | 0.3363 | 0.0604 | -- | 1.51 | 55,992.59 | -84.00 | -49.86 | -97.02 | -54.21 | 87.95 | -- | -1,391.14 | -- | 7.21 | -82.77 | 0.9412 | -- | -- | -- | -44.85 | -- | 33.39 | -- |
| Janux Therapeutics Inc | 10.00m | -113.63m | 827.92m | 109.00 | -- | 0.8589 | -- | 82.79 | -1.83 | -1.83 | 0.1614 | 15.85 | 0.0097 | -- | -- | 91,743.12 | -11.02 | -12.49 | -11.25 | -12.85 | -- | -- | -1,136.25 | -822.69 | -- | -- | 0.00 | -- | -5.55 | -- | -64.69 | -- | -- | -- |
| Prime Medicine Inc | 5.98m | -197.34m | 833.96m | 214.00 | -- | 5.15 | -- | 139.53 | -1.44 | -1.44 | 0.0434 | 0.8975 | 0.0167 | -- | -- | 27,929.91 | -54.98 | -64.35 | -61.20 | -77.73 | -- | -- | -3,301.64 | -8,356.07 | -- | -- | 0.00 | -- | -- | -- | 1.14 | -- | -- | -- |
| Sellas Life Sciences Group Inc | 0.00 | -25.94m | 839.49m | 15.00 | -- | 13.51 | -- | -- | -0.2869 | -0.2869 | 0.00 | 0.3648 | 0.00 | -- | -- | 0.00 | -66.47 | -125.08 | -84.33 | -231.32 | -- | -- | -- | -1,399.79 | -- | -- | 0.00 | -- | -- | -- | 17.30 | -- | -- | -- |
| Arvinas Inc | 262.60m | -80.80m | 848.76m | 246.00 | -- | 1.94 | -- | 3.23 | -1.22 | -1.22 | 3.70 | 6.83 | 0.2903 | -- | 78.39 | 1,067,480.00 | -8.93 | -18.57 | -11.25 | -22.95 | -- | -- | -30.77 | -141.50 | -- | -- | 0.0009 | -- | -0.3037 | 64.50 | 59.38 | -- | -21.68 | -- |
| Omeros Corp | 0.00 | -121.24m | 854.35m | 202.00 | -- | -- | -- | -- | -2.04 | -2.02 | 0.00 | -3.15 | 0.00 | -- | -- | 0.00 | -48.59 | -50.90 | -66.86 | -63.20 | -- | -- | -- | -- | -- | -- | 2.72 | -- | -- | -- | -4.41 | -- | -13.15 | -- |
| Arbutus Biopharma Corp | 14.61m | -42.28m | 896.23m | 44.00 | -- | 11.56 | -- | 61.36 | -0.2219 | -0.2219 | 0.0764 | 0.4032 | 0.1227 | -- | 11.62 | 331,954.50 | -35.50 | -44.03 | -39.50 | -49.46 | -- | -- | -289.45 | -433.59 | -- | -- | 0.0454 | -- | -65.98 | 0.5268 | 4.02 | -- | -20.93 | -- |
| CytomX Therapeutics Inc | 113.63m | 28.02m | 909.87m | 119.00 | 13.34 | 8.25 | 31.06 | 8.01 | 0.4027 | 0.4027 | 0.9733 | 0.6506 | 0.7646 | -- | 45.63 | 954,882.40 | 18.85 | -15.58 | 40.91 | -26.48 | -- | -- | 24.66 | -50.39 | -- | -- | 0.00 | -- | 36.45 | 19.16 | 5,700.88 | -- | -38.41 | -- |
| Maravai Lifesciences Holdings Inc | 185.74m | -130.77m | 915.16m | 435.00 | -- | 4.29 | -- | 4.93 | -0.9059 | -0.9059 | 1.29 | 0.8296 | 0.2088 | 3.35 | 5.80 | 426,995.40 | -25.95 | 4.29 | -36.49 | 5.56 | 18.30 | 68.51 | -124.24 | 13.71 | 5.69 | -7.54 | 0.4642 | 0.00 | -28.34 | -8.15 | 9.72 | -- | -12.34 | -- |
| Cullinan Therapeutics Inc | 0.00 | -216.81m | 915.68m | 111.00 | -- | 2.03 | -- | -- | -3.68 | -3.68 | 0.00 | 7.64 | 0.00 | -- | -- | 0.00 | -38.12 | -16.54 | -40.13 | -17.34 | -- | -- | -- | -1,797.10 | -- | -- | 0.00 | -- | -- | -- | -9.28 | -- | -- | -- |
Data as of Mar 02 2026. Currency figures normalised to Sellas Life Sciences Group Inc's reporting currency: US Dollar USD
18.41%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 7.39m | 5.19% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 6.87m | 4.83% |
| Geode Capital Management LLCas of 31 Dec 2025 | 3.08m | 2.16% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 2.19m | 1.54% |
| Millennium Management LLCas of 31 Dec 2025 | 1.39m | 0.97% |
| Marshall Wace LLPas of 31 Dec 2025 | 1.34m | 0.94% |
| Two Sigma Investments LPas of 31 Dec 2025 | 1.08m | 0.76% |
| Teachers Advisors LLCas of 31 Dec 2025 | 997.38k | 0.70% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 957.47k | 0.67% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 2025 | 930.75k | 0.65% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
